New Ovarian Cancer Therapy Triples Response Rate vs Chemotherapy

[{"selector":"#anim-164b8167-cfd4-4af7-84a9-7f08f79bc256","keyframes":{"opacity":[0,1]},"delay":500,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-500c0585-eff2-4952-a4d4-927ccd6b315d","keyframes":{"transform":["translate3d(-114.55696%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":500,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-b9082893-15f6-43a4-b655-ba2c628c62ae","keyframes":{"opacity":[0,1]},"delay":800,"duration":500,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-d9ba837d-1cbe-4bb4-9f59-04b544be487c","keyframes":{"transform":["translate3d(-122.3301%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":800,"duration":500,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] New Ovarian Cancer Therapy Triples Response Rate vs Chemotherapy Tejal Somvanshi

Low-grade serous ovarian cancer affects younger women and resists standard treatments, but scientists have mapped a new path forward.

[{"selector":"#anim-3b7c2b0d-07fa-4d54-83db-2fc68a319377","keyframes":{"opacity":[0,1]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-ce8c1246-a76a-469f-ae53-4176438f4244","keyframes":{"transform":["translate3d(115.50632%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-8cd0e608-cca1-483e-8fc8-125a3a13ae19","keyframes":{"opacity":[0,1]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-a1de0929-15a1-4866-bf48-8a879e48844c","keyframes":{"transform":["translate3d(0px, 116.02864%, 0)","translate3d(0px, 0px, 0)"]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-05d9f24a-143a-49fb-8f80-df7087185f7f","keyframes":{"opacity":[0,1]},"delay":1400,"duration":3000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Photo Source: Edward Jenner

Traditional ovarian cancer treatments have remained unchanged for decades with platinum-based chemotherapy showing response rates below 15% for LGSC patients.

[{"selector":"#anim-dd52c665-01b2-4b0f-ae9c-a0cc0bd13565","keyframes":{"opacity":[0,1]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-51713bc9-2830-46cb-88b8-fa234e711cef","keyframes":{"transform":["translate3d(0px, 164.85115%, 0)","translate3d(0px, 0px, 0)"]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-a0c50ace-f1b0-4fd7-8935-c74246aaa165","keyframes":{"opacity":[0,1]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-1ca764fa-c273-433e-840d-f0a471d20bd9","keyframes":{"transform":["translate3d(0px, -111.1955%, 0)","translate3d(0px, 0px, 0)"]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-a79defcd-e342-471f-a18e-1520f92dfd50","keyframes":{"opacity":[0,1]},"delay":1400,"duration":3000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Photo Source: IAEA Imagebank (CC BY-SA 2.0)

Using cutting-edge Deep Visual Proteomics technology, researchers created molecular maps showing exactly how tumors evolve within tissue environments.

[{"selector":"#anim-fc7060d4-5927-409e-9ac3-172803a97fd3","keyframes":{"opacity":[0,1]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-b9c8210b-986d-4645-aadc-c5fa11f97ca5","keyframes":{"transform":["translate3d(0px, 116.58885%, 0)","translate3d(0px, 0px, 0)"]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-09d8f940-ed05-4c7a-9b29-3681f8f0f05f","keyframes":{"opacity":[0,1]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-6dd95924-e9af-4622-a0fe-7383480c17ee","keyframes":{"transform":["translate3d(113.60759%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-f854d347-d3fd-4f07-b9f8-ae098d08dcc4","keyframes":{"opacity":[0,1]},"delay":1400,"duration":3000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Photo Source: Pavel Danilyuk

Scientists identified the NOVA2 protein found only in invasive forms of the tumor - potentially a key "switch" driving cancer cell invasion.

[{"selector":"#anim-ff966024-cf0d-40c8-b4b6-3114e0c30499","keyframes":{"opacity":[0,1]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-7170b884-92d8-4e7e-9221-af38b0601a05","keyframes":{"transform":["translate3d(0px, 198.60021%, 0)","translate3d(0px, 0px, 0)"]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-0748255e-6bdb-4ea6-92e8-677ad8bb29b1","keyframes":{"opacity":[0,1]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-7dd6cc1a-023e-4076-97c8-d628dc1d5d63","keyframes":{"transform":["translate3d(0px, -114.48664%, 0)","translate3d(0px, 0px, 0)"]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-c89cc0a6-4dd7-4cbc-8932-b31d265e0cc5","keyframes":{"opacity":[0,1]},"delay":1400,"duration":3000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Photo Source: Rawpixel (CC0 1.0)

The groundbreaking research identified 16 potential drug targets and tested a novel combination therapy: Milciclib paired with Mirvetuximab.

[{"selector":"#anim-d9d2bed6-8d51-4314-a435-0178bcf9c111","keyframes":{"opacity":[0,1]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-bfba6614-97eb-41fb-943a-8da84c4e6a2e","keyframes":{"transform":["translate3d(0px, 116.02864%, 0)","translate3d(0px, 0px, 0)"]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-bcb69b07-3af4-4542-97ba-d4607be6f573","keyframes":{"opacity":[0,1]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-e265bcf4-1582-47f9-8b34-72754f450950","keyframes":{"transform":["translate3d(115.18987%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-80a055a8-0ea5-44d2-94c6-f4f42cd0f28e","keyframes":{"opacity":[0,1]},"delay":1400,"duration":3000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Photo Source: Dorota Badowska (CC BY-SA 3.0 IGO)

How does this combination work? Milciclib blocks cell division while Mirvetuximab delivers a toxic payload specifically to cancer cells expressing the FOLR1 protein.

[{"selector":"#anim-33ac7db1-4714-41b0-a0e6-1b10951cdb8e","keyframes":{"opacity":[0,1]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-f5c931d7-57fb-45b3-9bb7-e24f34cfc484","keyframes":{"transform":["translate3d(0px, 164.85115%, 0)","translate3d(0px, 0px, 0)"]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-54238271-91b0-41d7-8718-655272e853ff","keyframes":{"opacity":[0,1]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-e1b250e7-f295-44eb-8ea7-60684d2f39d0","keyframes":{"transform":["translate3d(0px, -114.48664%, 0)","translate3d(0px, 0px, 0)"]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-d738f410-408b-4f3d-89d7-91961de74050","keyframes":{"opacity":[0,1]},"delay":1400,"duration":3000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Photo Source: NIH Image (PDM 1.0)

Clinical trials showed a 42.3% response rate with the new treatment compared to just 15.9% with standard chemotherapy - nearly triple the effectiveness.

[{"selector":"#anim-5ef704f8-ccb9-4ce5-8e56-9321901e05ca","keyframes":{"opacity":[0,1]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-68cd3e4e-1c55-4bc5-a838-555301103a68","keyframes":{"transform":["translate3d(0px, 116.02864%, 0)","translate3d(0px, 0px, 0)"]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-e8578ad7-0dc7-4b1e-a94a-8010954e0cf0","keyframes":{"opacity":[0,1]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-051214ac-03f5-402f-a33f-66bfee1b785a","keyframes":{"transform":["translate3d(115.18987%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-f08cac32-efc7-45df-b397-1428bdd69baf","keyframes":{"opacity":[0,1]},"delay":1400,"duration":3000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Photo Source: Artem Podrez

Mirvetuximab received FDA approval in March 2024 after studies showed it increased overall survival from 12.75 months to 16.46 months.

[{"selector":"#anim-e64b48ce-e193-4726-b6c1-c74cc082f54e","keyframes":{"opacity":[0,1]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-288c2eec-da86-4b5e-a02f-d50c72455700","keyframes":{"transform":["translate3d(0px, 199.3876%, 0)","translate3d(0px, 0px, 0)"]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-a379c23e-1df8-4681-bbb4-1b7211ee918b","keyframes":{"opacity":[0,1]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-696253eb-e2a1-4176-b5e6-4f01197801cd","keyframes":{"transform":["translate3d(0px, -114.48664%, 0)","translate3d(0px, 0px, 0)"]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-f848826e-7a1a-420b-9b11-fa739469d0e7","keyframes":{"opacity":[0,1]},"delay":1400,"duration":3000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Photo Source: Flickr (CC BY-NC-SA 2.0)

Treatment consists of an intravenous infusion once every three weeks, with duration of response averaging 6.9 months - significantly better than the 3-4 months with standard treatments.

[{"selector":"#anim-00c54246-a701-4651-affd-d5da7e69551a","keyframes":{"opacity":[0,1]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-30e73d38-9f0e-46cf-a638-8db02332cb07","keyframes":{"transform":["translate3d(0px, 116.02864%, 0)","translate3d(0px, 0px, 0)"]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-0fcb1cf2-0cd3-4156-8a55-5e334e7fcd5e","keyframes":{"opacity":[0,1]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-6f692564-8a43-4b87-acb4-43a32eb9aaea","keyframes":{"transform":["translate3d(115.18987%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-0860bd6a-a984-47e3-b1d8-690b182b04de","keyframes":{"opacity":[0,1]},"delay":1400,"duration":3000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Photo Source: IAEA Imagebank (CC BY-NC-ND 2.0)

Cost remains a significant hurdle - studies suggest a 70-73% reduction would be needed to meet standard cost-effectiveness thresholds.

[{"selector":"#anim-e6498451-7621-4dc1-9e98-1126d3140a17","keyframes":{"opacity":[0,1]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-11eb50ca-9a74-4db9-8480-1a5b7f2268ed","keyframes":{"transform":["translate3d(0px, 199.3876%, 0)","translate3d(0px, 0px, 0)"]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-a35e6de9-e263-4cff-a68d-5ef0229a9b5e","keyframes":{"opacity":[0,1]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-e7a37303-0f2b-44cd-98de-2252752c8c22","keyframes":{"transform":["translate3d(0px, -114.48664%, 0)","translate3d(0px, 0px, 0)"]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-334b676c-740b-4757-9ba9-e34e70f874d1","keyframes":{"opacity":[0,1]},"delay":1400,"duration":3000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Photo Source: Dorota Badowska (CC BY-SA 3.0 IGO)

"By mapping thousands of proteins at single-cell resolution, we can now visualize how tumors evolve in real-time," says Professor Matthias Mann.

[{"selector":"#anim-dde57190-f2ec-4363-aa71-0e15c70f1f15","keyframes":{"opacity":[0,1]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-4628bea0-b65e-4732-baba-a2a20623c0d9","keyframes":{"transform":["translate3d(0px, 165.50473%, 0)","translate3d(0px, 0px, 0)"]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-c2a13695-f04d-4050-9aca-aed4c9e42960","keyframes":{"opacity":[0,1]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-48e49845-e96f-40d5-947d-47da8770be72","keyframes":{"transform":["translate3d(0px, -114.48664%, 0)","translate3d(0px, 0px, 0)"]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-4764632c-179e-47fd-9fc4-61344664c882","keyframes":{"opacity":[0,1]},"delay":1400,"duration":3000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Photo Source: Polina Tankilevitch Learn more

For the 5-10% of ovarian cancer patients diagnosed with LGSC, these advances offer renewed hope for more effective and less toxic treatment options.

[{"selector":"#anim-33c9ecf7-f024-4633-8418-b814d529ec88","keyframes":{"opacity":[0,1]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-b826a572-d5dd-4e36-99e3-197b2310c412","keyframes":{"transform":["translate3d(0px, 165.50473%, 0)","translate3d(0px, 0px, 0)"]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-5dc75fb4-405a-4fb6-91be-e5d85ae694b5","keyframes":{"opacity":[0,1]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-b9271a66-c1e5-4710-a73f-3283132ada08","keyframes":{"transform":["translate3d(0px, -114.48664%, 0)","translate3d(0px, 0px, 0)"]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-d54f5ebb-a016-4adc-8852-a592933d2014","keyframes":{"opacity":[0,1]},"delay":1400,"duration":3000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Photo Source: Osprey P.Clinic (CC BY-NC 4.0)

[{"selector":"#anim-33cb1401-45b6-4577-a7d3-add4415013a8","keyframes":{"opacity":[0,1]},"delay":200,"duration":3000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-194d0c58-dd0d-4bd2-83d5-7a3396b790b7","keyframes":{"opacity":[0,1]},"delay":200,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-f28aee2d-27e8-4cdf-b143-440bad43f58e","keyframes":{"transform":["translate3d(-114.50152%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":200,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-642b356e-5eed-475c-9579-c67893d52adf","keyframes":{"opacity":[0,1]},"delay":700,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-d4df638e-4236-4fef-84f9-a6b4c527e9ae","keyframes":{"transform":["translate3d(115.2381%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":700,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] 400 Pancreas Problems: Weight Loss Drugs Under Investigation Learn more